Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced the presentation of results from the Company’s Phase 1A study in healthy volunteers evaluating oral non-covalent reversible BTK …
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced the pricing of underwritten offerings of (i) 4,935,500 shares of its common stock at a price of $3.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that it has submitted its responses to European Medicines Agency (EMA) Day 120 List of Questions issued by the …
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a …
Cowen analyst Eric Schmidt weighed in today with a few insights on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), after the company reported second-quarter financials and provided investors …
LinkedIn Corp (NYSE:LNKD) is up a whopping 48% after Microsoft agreed to buy the company for $26.2 billion in cash.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced the presentation of updated results from an ongoing Phase 1b/2University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin …
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that Linda Neuman, M.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced its support for the first-ever Acute Myeloid Leukemia Awareness Month to be held in June.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) reported financial results for the fourth quarter and year ended December 31, 2015.